Merus Labs International Inc. Announces Board Changes
TORONTO, ONTARIO -- (Marketwired) -- 07/09/13 -- Merus Labs
International Inc. ("Merus" or the "Company") (TSX:MSL)(NASDAQ:MSLI)
is pleased to announce that it has appointed Mr. Michael Cloutier to
the Company's Board of Directors, effective immediately.
Mr. Cloutier will serve as an independent non-executive Director and
is a seasoned pharmaceutical executive with international experience.
His past roles have included President and CEO of Astra Zeneca
Canada, President of Pharmacia Canada, and CEO of Critical Outcomes
Technology Inc., an early stage biotechnology company. Most recently,
Mr. Cloutier was the CEO of the Canadian Diabetes Association and is
currently the President and General Manager of InterMune Inc., a
biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan
fibrotic diseases. From his numerous leadership roles, Mr. Cloutier
brings extensive managerial, operational, and commercial expertise to
the Merus Board.
The Board change was facilitated following a request by Mr. Rus to
resign from the Board due to health reasons. The Board of Directors
takes this opportunity to thank Mr. Rus for his valued contributions
as the Chairman of the Board and the pivotal role he played in the
development of the Company. The Directors wish Mr. Rus well in his
future endeavours. Mr. David Guebert, a current Director of the
Company, will assume the Chairmanship of the Merus Board effective
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the
acquisition and licensing of pharmaceutical products. The Company
utilizes its expertise in pharmaceutical markets and its access to
capital to acquire and license niche branded products. Merus further
enhances the sale and distribution of these products by the
introduction of a focused marketing and promotion plan.
Certain statements contained in this press release may constitute
"forward-looking statements" within the meaning of Section 21E (i)
(1) of the United States Securities Exchange Act of 1934. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Merus' actual results
to be materially different from any future results expressed or
implied by these statements. Such factors include the following:
general economic and business conditions, changes in demand for
Merus' products, changes in competition, the ability of Merus to
integrate acquisitions or complete future acquisitions, interest rate
fluctuations, currency exchange rate fluctuations, dependence upon
and availability of qualified personnel and changes in government
regulation. In light of these and other uncertainties, the
forward-looking statements included in this press release should not
be regarded as a representation by Merus that Merus' plans and
objectives will be achieved. These forward-looking statements speak
only as of the date of this press release, and we undertake no
obligation to update or revise the statements.
Merus Labs International Inc.
President and CEO
Press spacebar to pause and continue. Press esc to stop.